Global Ventricular Assist Devices Market to Grow at 11% CAGR, Driven by Heart Failure Cases by 2030

The global ventricular assist devices (VAD) market is projected to grow at a CAGR of ~11% during the forecast period. This growth is primarily driven by the rising prevalence of heart failure, the growing geriatric population, innovations such as magnetically levitated pumps and percutaneous systems, increasing adoption of VADs as destination therapy, favourable reimbursement policies, and the shift toward minimally invasive and wearable VADs. However, the high cost of VAD implantation and maintenance continues to be a major restraint for broader adoption. 

Ventricular assist devices (VADs) are mechanical pumps that support heart function and blood flow in individuals with weakened hearts, particularly those experiencing advanced heart failure. These devices are surgically implanted to assist either the left ventricle (LVAD), right ventricle (RVAD), or both (BiVAD) in pumping blood effectively to the rest of the body. VADs are mainly used as a bridge to transplant, providing life-sustaining support for patients waiting for a heart transplant, or as destination therapy for patients who are ineligible for transplant. They are also employed as a bridge to recovery, allowing the heart to rest and regain function in case of temporary heart failure. VADs can be implantable for long-term use or extracorporeal (outside the body) for short-term or emergency support, such as in cases of cardiogenic shock. These devices are commonly used in hospitals with advanced cardiac care units and are increasingly adopted in specialty clinics. Continuous-flow VADs are currently the most widely adopted devices as they are smaller and more durable. With the rise in cases of heart failure globally, VADs play a crucial role in improving survival, reducing symptoms, and enhancing the quality of life for patients with end-stage cardiac conditions.

Download a free sample report for in-depth market insights
https://meditechinsights.com/ventricular-assist-devices-market/request-sample/

Increasing prevalence of heart failure is fueling growth of the ventricular assist devices market

One of the primary drivers of the ventricular assist devices (VAD) market is the increasing global prevalence of heart failure. According to an article published by NIH in 2023, over 64 million people worldwide had heart failure, and this number is steadily rising, primarily due to aging populations, especially in developed regions. The surge is also due to growing adoption of sedentary lifestyles, poor dietary habits, and higher rates of hypertension, diabetes, and obesity.

As heart failure advances to more severe stages, patients often face debilitating symptoms like breathlessness, fatigue, and fluid retention, which greatly impact their quality of life and survival. In advanced cases, traditional treatments like medication or lifestyle changes become less effective, and heart transplants are considered the gold standard. However, due to the long wait times for transplants, ventricular assist devices have become an essential alternative. VADs can serve as a bridge-to-transplant, bridge-to-recovery, or even as destination therapy for patient’s ineligible for transplant, providing vital circulatory support and enhancing both survival and quality of life. The increasing burden of heart failure thus directly fuels the demand for VADs across hospitals and cardiac care centers worldwide.

Increasing market adoption of minimally invasive and percutaneous VADs

The VADs market is experiencing a major shift with the increasing use of minimally invasive, percutaneous devices (pVADs) for acute circulatory support. Unlike traditional surgically implanted VADs, pVADs are inserted through small catheters, usually via the femoral artery, avoiding open-heart surgery. This change is mainly driven by the urgent need to lower procedural risk, decrease vascular complications, and shorten patient recovery times, especially in emergencies like cardiogenic shock and high-risk percutaneous coronary interventions (PCI).

With the surge in the number of heart failures, particularly among older populations and those with multiple health issues, clinicians are increasingly relying on pVADs for quick and effective hemodynamic support. These devices provide the benefit of delivering high blood flow up to 5 litres per minute, through small catheters as narrow as 10–14 French and are simpler to implant and remove, which is vital in time-critical cardiac procedures. Recent clinical trial outcomes, including devices from companies like Magenta Medical, Supira Medical, and CSI, have shown that percutaneous options can be both safe and highly effective. Consequently, pVADs are rapidly becoming the first choice for short-term mechanical circulatory support, particularly in interventional cardiology settings.

Recent developments in the ventricular assist devices market

Recent FDA approvals highlight growing innovation and clinical refinement in the VAD market. These developments are streamlining access to safer and more advanced device options. For instance,

• In August 2024, Abbott announced that the FDA had approved a change to its label that will support, exclusively, patients who receive a HeartMate 3 left ventricular assist device to experience superior clinical outcomes by eliminating aspirin as part of routine patient management
• In August 2023, the FDA designated magAssist’s NyokAssist interventional VAD as a “Breakthrough Device”, the first cardiac device from China to earn this title. This title will accelerate its regulatory review and highlights its potential to expand VAD access, especially amid rising global heart failure cases

Competitive Landscape Analysis

The global ventricular assist devices market is marked by the presence of established and emerging market players such as Abbott Laboratories; Medtronic Plc; Berlin Heart GmbH; Jarvik Heart, Inc.; Cardiac Assist, Inc (LivaNova PLC); Evaheart, Inc.; Abiomed, Inc. (Johnson & Johnson company); SynCardia Systems, LLC; Sun Medical Technology Research Corporation; BiVACOR Inc; and AdjuCor GmbH among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

 Unlock key data with a sample report for competitive analysis:
https://meditechinsights.com/ventricular-assist-devices-market/request-sample/

Global Ventricular Assist Devices Market Segmentation

This report by Medi-Tech Insights provides the size of the global ventricular assist devices market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, flow type, application and end-user.

Market Size & Forecast (2023-2030), By Product, USD Million

• Left Ventricular Assist Device (LVAD)
• Right Ventricular Assist Device (RVAD)
• Bi-Ventricular Assist Device (BiVAD)
• Total Artificial Heart

Market Size & Forecast (2023-2030), By Pump Flow Type, USD Million

• Continuous Flow
• Pulsatile Flow

Market Size & Forecast (2023-2030), By Application, USD Million

• Bridge to Transplant (BTT)
• Destination Therapy (DT)
• Bridge to Recovery (BTR)
• Others

Market Size & Forecast (2023-2030), By End-user, USD Million

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
• US
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
• Latin America
• Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com